阻塞性睡眠呼吸暂停低通气综合征与成纤维细胞生长因子21

doi:10.6040/j.issn.1673-3770.0.2016.319

摘要/Abstract

摘要： 阻塞性睡眠呼吸暂停低通气综合征(OSAHS)发病率逐年升高,已经成为危害人类健康的主要疾病之一。迄今为止,OSAHS 的发病机制尚未阐明。成纤维细胞生长因子21(FGF21)是参与糖脂代谢的一种重要蛋白质。近年来大量的研究显示FGF21与OSAHS的发生发展有密切的联系。本文就近些年OSAHS与FGF21的相关研究进行简要综述。

关键词: 睡眠呼吸暂停低通气综合征, 能量代谢, 成纤维细胞生长因子21, 糖脂代谢

Abstract: The prevalence of OSAHS has been dramatically increasing during the last decade, which has become one of the major diseases that endangers human health. The pathogenesis of OSAHS is not yet fully clear. Some studies have shown that FGF21 is closely linked with OSAHS. The correlation between FGF21 and OSAHS will be discussed in this chapter.

Key words: Fibroblast growth factor 21, Glucose and lipid metabolism, Energy metabolism, Obstructive sleep apnea hypopnea syndrome

中图分类号:

R766.7

梁小红,李艳综述, 李翀审校. 阻塞性睡眠呼吸暂停低通气综合征与成纤维细胞生长因子21[J]. 山东大学耳鼻喉眼学报, 2016, 30(5): 81-84.

LIANG Xiaohong, LI Yan, LI Chong. Obstructive sleep apnea hypopnea syndrome and Fibroblast growth factor 21.[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(5): 81-84.

参考文献

[1] Nishimura T, Nakatake Y, Konishi M, et al. Identification of a novel FGF, FGF-21, preferentially expressed in the liver[J]. Biochim Biophys Acta, 2000, 1492(1):203-206.
[2] Iglesias P, Selgas R, Romero S, et al. Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21[J]. Eur J Endocrinol, 2012, 167(3):301-309.
[3] Nies V J, Sancar G, Liu W, et al. Fibroblast growth factor signaling in metabolic regulation[J]. Front Endocrinol(Lausanne), 2015, 6:193.
[4] Indrakusuma I, Sell H, Eckel J. Novel mediators of adipose tissue and muscle crosstalk[J]. Curr Obes Rep, 2015, 4(4):411-417.
[5] Owen B M, Mangelsdorf D J, Kliewer S A. Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21[J]. Trends Endocrinol Metab, 2015, 26(1):22-29.
[6] Zhao Y, Dunbar J D, Kharitonenkov A. FGF21 as a therapeutic reagent[J]. Adv Exp Med Biol, 2012, 728(2):214-228.
[7] So W Y, Leung P S. Fibroblast growth factor 21 as an emerging therapeutic target for Type 2 diabetes mellitus[J]. Med Res Rev, 2016, 36(4):672-704.
[8] Chau M D, Gao J, Yang Q, et al. Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway[J]. Proc Natl Acad Sci U S A, 2010, 107(28):12553-12558.
[9] 芮欣忆, 阮晓楠,周先锋,等.上海市浦东新区20~74岁居民超重、肥胖、中心性肥胖的现况调查及流行特征[J].中华内分泌代谢杂志, 2016, 32(3):206-212. RUI Xinyi, RUAN Xiaonan, ZHOU Xianfeng, et al. Prevalence and epidemic characteristic of overweight, obesity, and central obesity in Shanghai Pudong New[J]. Chin J Endocrinol Metab, 2016, 32(3):206-212.
[10] 中华医学会呼吸病学会睡眠呼吸障碍学组,阻塞性睡眠呼吸暂停低通气综合征诊治指南(2011年修订版)[J].中华结核和呼吸杂志,2012,35(1):9-12. Chinese Medical Association of respiratory disease sleep respiratory disorder group, Clinical Practice Guidelines on traetment of obstructive sleep apnea sydrome[J]. Chin J Tuber Resp Dis, 2012, 35(1):9-12.
[11] Parekh R, Green E, Majeed A. Obstructive sleep apnoea: quantifying its association with obesity and snoring[J]. Prim Care Respir J, 2012, 21(4):361-362.
[12] Romero-Corral A, Caples S M, Lopez-Jimenez F, et al. Interactions between obesity and obstructive sleep apnea: implications for treatment[J]. Chest, 2010, 137(3):711-719.
[13] Giralt M, Gavalda-Navarro A, Villarroya F. Fibroblast growth factor-21, energy balance and obesity[J]. Mol Cell Endocrinol, 2015, 418:66-73.
[14] Fisher F M, Chui P C, Antonellis P J, et al. Obesity is a fibroblast growth factor 21(FGF21)-resistant state[J]. Diabetes, 2010, 59(11):2781-2789.
[15] Reinehr T, Woelfle J, Wunsch R, et al. Fibroblast growth factor 21(FGF-21)and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis[J]. J Clin Endocrinol Metab, 2012, 97(6):2143-2150.
[16] Zhang J, Li Y. Fibroblast growth factor 21 analogs for treating metabolic disorders[J]. Front Endocrinol(Lausanne), 2015, 6:168.
[17] Hui P, Jia S, Ma W, et al. The clinical significance and changes of serum tumor necrosis factor and plasma endothelium in patients with OSAHS associated Type 2 diabetes mellites[J]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, 2016, 30(3):217-219, 225.
[18] Xu J, Long Y S, Gozal D, et al. Beta-cell death and proliferation after intermittent hypoxia: role of oxidative stress[J]. Free Radic Biol Med, 2009, 46(6):783-790.
[19] Fan H, Sun X, Zhang H, et al. Effect of metformin on fibroblast growth factor-21 levels in patients with newly diagnosed Type 2 diabetes[J]. Diabetes Technol Ther, 2016, 18(3):120-126.
[20] Adams A C, Halstead C A, Hansen B C, et al. LY2405319, an engineered FGF21 variant, improves the metabolic status of diabetic monkeys[J]. PLoS One, 2013, 8(6):e65763.
[21] Mu J, Pinkstaff J, Li Z, et al. FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents[J]. Diabetes, 2012, 61(2):505-512.
[22] Lin Z, Tian H, Lam K S, et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice[J]. Cell Metab, 2013, 17(5):779-789.
[23] Anker S D, von Haehling S, Germany R. Sleep-disordered breathing and cardiovascular disease[J]. Indian Heart J, 2016, 68(1):69-76.
[24] Cheng P, Zhang F, Yu L, et al. Physiological and pharmacological roles of FGF21 in cardiovascular diseases[J]. J Diabetes Res, 2016, 2016:1540267.
[25] Chow WS, Xu A, Woo YC, et al. Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors[J]. Arterioscler Thromb Vasc Biol, 2013, 33(10):2454-2459.
[26] Jin L, Lin Z, Xu A. Fibroblast growth factor 21 protects against atherosclerosis via fine-tuning the multiorgan crosstalk[J]. Diabetes Metab J, 2016, 40(1):22-31.
[27] Lin Z, Pan X, Wu F, et al. Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice[J]. Circulation, 2015, 131(21):1861-1871.
[28] Cuevas-Ramos D, Aguilar-Salinas C A. Modulation of energy balance by fibroblast growth factor 21[J]. Horm Mol Biol Clin Investig, 2016.
[29] Hanssen M J, Broeders E, Samms R J, et al. Serum FGF21 levels are associated with brown adipose tissue activity in humans[J]. Sci Rep, 2015, 5:10275.
[30] Takx R, Ishai A, Truong Q A, et al. Supraclavicular Brown adipose tissue FDG uptake and cardiovascular disease[J]. J Nucl Med, 2016, 57(8):1221-1225.

相关文章 15

[1]	张会芳,杨红珍. 经鼻持续气道正压通气对阻塞性睡眠呼吸暂停低通气[J]. 山东大学耳鼻喉眼学报, 2018, 32(2): 48-51.
[2]	孙娜综述,陈晓平审校. 咽喉反流与耳鼻咽喉科疾病[J]. 山东大学耳鼻喉眼学报, 2016, 30(6): 85-89.
[3]	高天喜,夏翠,闫静,侯瑾,康全清,王正辉,任晓勇. 间歇低氧模型大鼠肝脏组织中IGF-1、IGFBP-3的表达及分析[J]. 山东大学耳鼻喉眼学报, 2016, 30(5): 38-41.
[4]	于青青,唐隽,王跃建. 建立扁桃体腺样体不同手术方式对儿童阻塞性睡眠呼吸暂停低通气综合征疗效的系统评价体系[J]. 山东大学耳鼻喉眼学报, 2016, 30(5): 42-48.
[5]	章榕,王洪洪,余蕾蕾,刘亮,孙建军,李进让,展慕霞. 多导睡眠监测与便携式睡眠监测的临床应用比较[J]. 山东大学耳鼻喉眼学报, 2016, 30(5): 65-67.
[6]	葛星, 吕玲双, 潘铭, 时巧梅, 许建峰, 林友结, 孙雅慧, 神平. 打鼾相关流行病学现状及其影响因素调查研究——以徐州地区为例[J]. 山东大学耳鼻喉眼学报, 2014, 28(5): 10-13.
[7]	梁送民1，郭永伟2综述，赵霞1审校. 便携式睡眠监测仪对阻塞性睡眠呼吸暂停综合征的诊断价值[J]. 山东大学耳鼻喉眼学报, 2014, 28(2): 22-25.
[8]	夏春鹏1，林燕辉2，李岩1，李克义1，张彬2. 口腔矫治器治疗对OSAHS患者焦虑抑郁及心理状态影响的研究[J]. 山东大学耳鼻喉眼学报, 2014, 28(2): 29-32.
[9]	罗惠秀，范春涛，邓延华. 阻塞性睡眠呼吸暂停低通气综合征患儿扁桃体腺样体切除术临床疗效分析[J]. 山东大学耳鼻喉眼学报, 2013, 27(4): 17-20.
[10]	杨嵘，宗涛，孙亚男，陆金发. 持续正压通气联合卡托普利、硝苯地平治疗重度阻塞性睡眠呼吸暂停低通气综合征合并高血压疗效观察[J]. 山东大学耳鼻喉眼学报, 2013, 27(3): 10-12.
[11]	谭杰，杨建国，王德生，刘健治，胡晓华，黄建民. 鼻腔扩容术治疗OSAHS疗效分析[J]. 山东大学耳鼻喉眼学报, 2012, 26(6): 10-12.
[12]	许振跃方铭达洪斌李兆生. 软腭、舌体低温等离子消融配合H-UPPP治疗重度OSAHS 30例分析[J]. 山东大学耳鼻喉眼学报, 2009, 23(4): 12-14.
[13]	张建基,孙晓卫,程璐,牟鸿,窦芬芬,巩克波,江应慧 . 儿童OSAHS不同刺激重复率听性脑干反应的临床研究[J]. 山东大学耳鼻喉眼学报, 2007, 21(6): 515-517 .
[14]	王卫之,王岩,张代杰 . 老年阻塞性睡眠呼吸暂停低通气综合征患者睡眠监测及治疗特点[J]. 山东大学耳鼻喉眼学报, 2007, 21(6): 518-520 .
[15]	杨晨,陈学明,蔡昌枰,王士礼,何士方,李敏,曹蓓,倪瑾华 . 阻塞性睡眠呼吸暂停低通气综合征患者健康相关生命质量与多导睡眠监测结果相关性[J]. 山东大学耳鼻喉眼学报, 2007, 21(6): 511-514 .

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed